Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascelia Pharma AB ( (SE:ACE) ) has issued an announcement.
Ascelia Pharma has appointed its Nomination Committee for the Annual General Meeting to be held in Malmö on 4 May 2026, in line with its governance rules that require representatives from the three largest shareholders together with the chairman of the board. The committee, chaired by Oscar Ahlgren of Salenia and including representatives from major shareholders as well as board chairman Peter Benson, will prepare proposals on board composition, remuneration, auditor selection and principles for future nomination processes, and has invited shareholders to submit proposals by 15 March 2026, underscoring ongoing shareholder engagement and adherence to Swedish corporate governance standards.
More about Ascelia Pharma AB
Ascelia Pharma AB is a Swedish biotech company focused on orphan oncology treatments, developing and commercializing novel drugs that address unmet medical needs with a clear development and market pathway. The company currently has two drug candidates in development, Orviglance and Oncoral, is headquartered in Malmö, and is listed on Nasdaq Stockholm under the ticker ACE.
YTD Price Performance: 8.22%
Average Trading Volume: 1,503,268
Technical Sentiment Signal: Sell
Current Market Cap: SEK400.9M
For a thorough assessment of ACE stock, go to TipRanks’ Stock Analysis page.